Keeping Track: KemPharm Apadaz Delay; Cholera Vaccine Approved
Executive Summary
The latest drug development news and highlights from our FDA Performance Tracker. Vaxchora cholera vaccine is CBER's fourth novel biologic cleared this year; Adamis emergency Epi turned down again.
You may also be interested in...
Chikungunya Vaccine Development May Rely On Immunologic Biomarkers Instead Of Traditional Trials
As the mosquito-borne chikungunya virus spreads into temperate regions worldwide, US FDA convenes advisory committee for an open discussion on development of vaccines.
Complex Products At US FDA: Adamis' Epi-Pen Alternative OKed; Sandoz Advair ANDA Accepted
The latest regulatory news on new versions of complex products and delivery systems from our FDA Performance Tracker.
Complex Products At US FDA: Adamis' Epi-Pen Alternative OKed; Sandoz Advair ANDA Accepted
The latest regulatory news on new versions of complex products and delivery systems from our FDA Performance Tracker.